Harrow presented three clinical and real-world studies for IHEEZO and BYOOVIZ at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting. These presentations expand the clinical evidence supporting the company's retina portfolio.
Interim findings from a 150-patient trial showed IHEEZO resulted in less post-procedure pain and a better patient experience than subconjunctival lidocaine. A separate real-world study involving nearly 20,000 injections indicated no increased risk of endophthalmitis with IHEEZO use.
Large-scale post-marketing surveillance data for BYOOVIZ reinforced a safety profile comparable to its reference product, Lucentis.